valsartan
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Nov 1, 2004 → Jul 1, 2007
NCT ID
NCT00343499About valsartan
valsartan is a approved stage product being developed by Novartis for Atrial Fibrillation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00343499. Target conditions include Atrial Fibrillation.
What happened to similar drugs?
20 of 20 similar drugs in Atrial Fibrillation were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01541189 | Approved | Completed |
| NCT00627991 | Pre-clinical | Withdrawn |
| NCT00550095 | Approved | Completed |
| NCT00457626 | Phase 3 | Completed |
| NCT01425411 | Approved | Completed |
| NCT00589732 | Approved | Completed |
| NCT00415883 | Phase 1 | Completed |
| NCT00394745 | Phase 3 | Completed |
| NCT00343499 | Approved | Terminated |
| NCT00170924 | Approved | Completed |
| NCT00171353 | Approved | Completed |
| NCT00333489 | Approved | Completed |
| NCT00171119 | Approved | Terminated |
| NCT00171028 | Phase 3 | Completed |
| NCT00241137 | Phase 3 | Completed |
| NCT00241098 | Approved | Completed |
| NCT00171041 | Phase 3 | Completed |
| NCT00171106 | Approved | Completed |
| NCT00241150 | Approved | Completed |
| NCT00241085 | Approved | Completed |
Competing Products
20 competing products in Atrial Fibrillation